AAM Applauds House Introduction of Skinny Labeling Bill
Allows quicker market entry of generic and biosimilar competition, reducing prices across the healthcare landscape, protecting patient access to affordable medicines WASHINGTON (December 8, 2025) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, applauds and supports The Skinny Labels, Big Savings Act, which today was introduced in the […]
AAM Congratulates Dr. Oz on Confirmation as Administrator of the Centers for Medicare & Medicaid Services
WASHINGTON (April 3, 2025) — The Association for Accessible Medicines today congratulated Dr. Mehmet Oz, M.D., on Senate confirmation to lead the Centers for Medicare & Medicaid Services. “Congratulations to Dr. Oz on confirmation to lead CMS,” said John Murphy III, President and CEO of the Association for Accessible Medicines. “Generic and Biosimilar medicines provide […]
The IRA Hurts Generic and Biosimilar Medication Competition
Supporters of the “price negotiation” process established in the Inflation Reduction Act (IRA) claimed that it would not harm generic or biosimilar competition. They explained that the IRA’s price negotiations would take effect only when a generic or biosimilar version of a drug is not available. However, they neglected to share, or failed to realize, […]
Redesigned Medicare Drug Program Still Allows PBMs to Deny Patients Access to Lower-Cost Generics & Biosimilars
At a time when public opinion is often divided, Americans are remarkably aligned on two things: prescription drug prices as a whole are too high, and generic medicines bring lower prices. This is backed up by the facts. The use of generic and biosimilar medicines has generated more than $3.1 trillion in savings to U.S. […]
AAM Comments on Medicare Drug Price Negotiation List
WASHINGTON (January 17, 2025) — The Association for Accessible Medicines, the trade association for generic and biosimilar manufacturers, today commented on the release of fifteen medications added to the list for Medicare drug price negotiations. “By including drugs with generics and biosimilars in development in the 15 drugs selected for negotiation, CMS highlights a central […]
Medicare Plans Continue Trend of Restricting Generic Drugs
Avalere analysis finds 57% of covered generic drugs not on Part D generic tiers in 2025 WASHINGTON, DC (December 10, 2024) – The Association for Accessible Medicines, the trade association for generic and biosimilar manufacturers, commented on an analysis released by Avalere showing that Medicare plans continue to increase patient costs for generic medicines. “Despite […]
Benefit Projected by CMS Price Setting Cannot Compare to Benefit of Generic and Biosimilar Medicines
Healthy competition and access to generics and biosimilars are essential for patients and the U.S. healthcare system WASHINGTON (August 15, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, today commented on the recent announcement from the U.S. Department of Health and Human Services regarding a fact sheet […]
Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?
Prescription plans continue to increase patient copays for generics by moving them to higher tiers.
Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?
Last month, as part of its Fiscal Year 2025 budget, the Biden Administration proposed a new initiative under the Medicare Part D program to require all Part D plans to offer a standard list of generic drugs with a maximum copayment of $2 per 30-day supply. This came on the heels of an Issue Brief […]
Medicare Plans Increase Patient Costs for Generic Medicines
Avalere Analysis finds that fewer than half of all generic drugs are on generic formulary tiers WASHINGTON (February 20, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, commented on an analysis released today by Avalere showing that Medicare plans increase patient costs for generic medicines. “Avalere’s analysis […]
AAM Statement on President Biden’s Budget Plan
WASHINGTON, D.C. (March 7, 2023) – The Association for Accessible Medicines Interim CEO, David Gaugh, today released the following statement regarding President Biden’s budget plan. “While we await further details about the President’s budget, proposals to expand the Inflation Reduction Act’s Medicare negotiations and inflation-based penalties only create more uncertainty for the development of lower-cost generic […]
AAM Statement on CMMI Report
WASHINGTON, DC (February 15, 2023) — The Association for Accessible Medicines (AAM) today issued a statement on the latest CMMI report: “As the Biden Administration has recognized in its Comprehensive Plan for Addressing High Drug Prices, lower-cost generic and biosimilar medicines hold enormous promise to reduce prescription drug costs and increase access for seniors,” said Craig […]
